Skip to main content

People in the News: Jan 6, 2011

Premium

Advent Venture Partners has named Dale Pfost as a venture partner.

Pfost previously served as CEO and chairman of Acuity Pharmaceuticals, an siRNA-based drug developer that was later acquired by Opko Health.


Regulus Therapeutics has promoted Garry Menzel to COO and executive vice president of finance.

He previously served as executive vice president of corporate development and finance. Before joining Regulus, Menzel was a managing director at Credit Suisse. Before that, he was a managing director at Goldman Sachs.

He has a BSc in biochemistry from the Imperial College of Science & Technology, and a PhD in molecular biology from the University of Cambridge. He also received an MBA from the Stanford Graduate School of Business.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.